The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Open accessAbstract
Assessment of Alzheimer's disease (AD)-related neurofibrillary pathology requires a procedure that permits a sufficient differentiation between initial, intermediate, and late stages. The gradual deposition of a hyperphosphorylated tau protein within select neuronal types in specific nuclei or areas is central to the disease process. The staging of AD-related neurofibrillary pathology originally described in 1991 was performed on unconventionally thick sections (100 mum) using a modern silver technique and reflected the progress of the disease process based chiefly on the topographic expansion of the lesions. To better meet the demands of routine laboratories this procedure is revised here by adapting tissue selection and processing to the needs of paraffin-embedded sections (5-15 mum) and by introducing a robust immunoreaction (AT8) for hyperphosphorylated tau protein that can be processed on an automated basis. It is anticipated that this revised methodological protocol will enable a more uniform application of the staging procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of Aβ plaques and NFTs follows distinct regional progressions across brain regions as AD advances.”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with the stereotypical hierarchical accumulation of NFTs along neural networks20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They were categorized into the stage C of amyloid deposition and the stage VI of neurofibrillary degeneration, following the Braak's staging (13).”
From Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease (2017) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“by definition, the primary visual cortex (V1 region) bears NFTs only in Braak NFT stage VI20,21”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“we rank ordered the five brain regions based on their known vulnerability to neurofibrillary degeneration20,21 (that is, EC > ITG > PFC > V2 > V1)”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“the distinguishing feature between Braak NFT stages V and VI is not just the presence of NFTs in the primary visual (V1), motor and sensory cortical areas, but more severe neurofibrillary degeneration21 and atrophy throughout the cortical mantle51”
From Astrocyte transcriptomic changes along the spatiotemporal progression of Alzheimer’s disease (2024) · cites this paper as [21]
In the citing paper
“A further pathological determinant is loss of neurons, which occurs predominantly in the cortex, the hippocampal formation, and the nucleus basalis of Meynert [2, 3, 18, 22, 25].”
From Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice (2008) · cites this paper as [2]
In the citing paper
“We consider it to be an important clue that most brains from elderly human subjects show abnormalities that fall somewhere along particular continua of pathologic severity (60, 96-100).”
From Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Self-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
(1964) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1964.tb115841.x · Cited by 1,411
Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., & Van Hoesen, G. W. (1991) · Cerebral Cortex · doi:10.1093/cercor/1.1.103 · Cited by 1,380
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.
Delacourte, A., David, J. P., Sergeant, N., Buée, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., et al. (1999) · Neurology · doi:10.1212/wnl.52.6.1158 · Cited by 828
Bancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 769
Self-citation
Research works printed but not linked: 7
- Alzheimer A (1906) Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurolog Centralbl 23:1129–1136
- Bielschowsky M (1902) Die Silberimprägnation der Axenzylinder. Neurol Centralb 13:579–584
- Bielschowsky M (1903) Die Silberimprägnation der Neurofibrillen. Neurol Centralb 21:997–1006
- Bielschowsky M (1904) Die Silberimprägnation der Neurofibrillen. Einige Bemerkungen zu der von mir angegebenen Methode und den von ihr gelieferten Bildern. J Psychol Neurol 3:169–189
- Bielschowsky M (1905) Die Darstellung der Axenzylinder peripherischer Nervenfasern und der Axenzylinder zentraler markhaltiger Nervenfasern. Ein Nachtrag zu der von mir angegebenen Imprägnationsmethode der Neurofibrillen. J Psychol Neurol 4:228–231
- Bielschowsky M (1909) Eine Modifikation meines Silberimprägnations-verfahrens zur Darstellung der Neurofibrillen. J Psychol Neurol 12:135–137
- Duyckaerts C, He Y, Seilhean D, Delaère P, Piette F, Braak H, Hauw JJ (1994) Diagnosis and staging of Alzheimer’s disease in a prospective study involving aged individuals. Neurobiol Aging 15(Suppl 1):140–141
Cited by
Sorted by citations
Items 601–700 of 1,028
Cai, S., Huang, L., Zou, J., JING, L.-L., Zhai, B., Ji, G., von Deneen, K. M., Ren, J., Ren, A., & Initiative, A. D. N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115573 · Cited by 72
Wang, H., Wang, R., Xu, S., & Lakshmana, M. K. (2016) · Neuroscience Journal · doi:10.1155/2016/4732837 · Cited by 69
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: advances and limitations
Peplow, P., & Martinez, B. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.244784 · Cited by 74
Vandendriessche, C., Bruggeman, A., Cauwenberghe, C. V., & Vandenbroucke, R. E. (2020) · Cells · doi:10.3390/cells9112485 · Cited by 75
The link between amyloid β and ferroptosis pathway in Alzheimer’s disease progression
Majerníková, N., Marmolejo-Garza, A., Salinas, C. S., Luu, M. D. A., Zhang, Y., Trombetta-Lima, M., Tomin, T., Birner-Gruenberger, R., Lehtonen, Š., Koistinaho, J., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07152-0 · Cited by 73
Leinonen, V., Koivisto, A. M., Alafuzoff, I. I., Pyykkö, O. T., Rummukainen, J. K., zu Fraunberg, M. V. U., Jääskeläinen, J. E., Soininen, H. S., Rinne, J., & Savolainen, S. (2012) · Neurodegenerative Diseases · doi:10.1159/000335155 · Cited by 73
Self-citationOlder onset essential tremor: More rapid progression and more degenerative pathology
Louis, E. D., Faust, P. L., Vonsattel, J., Honig, L. S., Henchcliffe, C., Pahwa, R., Lyons, K. E., Rios, E., Erickson-Davis, C. R., Moskowitz, C. B., et al. (2009) · Movement Disorders · doi:10.1002/mds.22570 · Cited by 73
REV-ERBα mediates complement expression and diurnal regulation of microglial synaptic phagocytosis
Griffin, P., Sheehan, P. W., Dimitry, J. M., Guo, C., Kanan, M. F., Lee, J., Zhang, J., & Musiek, E. S. (2020) · eLife · doi:10.7554/elife.58765 · Cited by 73
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
Deters, K., Risacher, S. L., Kim, S., Nho, K. T., West, J. D., Blennow, K., Zetterberg, H., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161114 · Cited by 72
Olajide, O. J., Suvanto, M. E., & Chapman, C. A. (2021) · Biology Open · doi:10.1242/bio.056796 · Cited by 77
Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer’s disease
Cody, K. A., Langhough, R. E., Zammit, M. D., Clark, L. R., Chin, N. A., Christian, B. T., Betthauser, T. J., & Johnson, S. C. (2024) · Brain · doi:10.1093/brain/awae116 · Cited by 71
Dystrophic neurites of senile plaques in Alzheimer’s disease are deficient in cytochrome c oxidase
Pérez-Gracia, E., Torrejón-Escribano, B., & Ferrer, I. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0370-6 · Cited by 71
Ansoleaga, B., Garcia‐Esparcia, P., Pinacho, R., Haro, J. M., Ramos, B., & Ferrer, I. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.012 · Cited by 72
Rentz, D. M., Mormino, E. C., Papp, K. V., Betensky, R. A., Sperling, R. A., & Johnson, K. A. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-016-9640-4 · Cited by 74
Carr, V. A., Bernstein, J. D., Favila, S. E., Rutt, B. K., Kerchner, G. A., & Wagner, A. D. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713308114 · Cited by 76
Rayaprolu, S., Gao, T., Xiao, H., Ramesha, S., Weinstock, L. D., Shah, J., Duong, D. M., Dammer, E. B., Webster, J. A., Lah, J. J., et al. (2019) · doi:10.1101/802694 · Cited by 71
Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology
Monsell, S. E., Mock, C., Hassenstab, J., Roe, C. M., Cairns, N. J., Morris, J. C., & Kukull, W. (2014) · Neurology · doi:10.1212/wnl.0000000000000650 · Cited by 71
Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study
Chen, S.-D., Lu, J.-Y., Li, H.-Q., Yang, Y.-X., Jiang, J.-H., Cui, M., Zuo, C.-T., Tan, L., Dong, Q., Yu, J.-T., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01602-5 · Cited by 71
Preman, P., Julia, T. C. W., Calafate, S., Snellinx, A., Alfonso-Triguero, M., Corthout, N., Munck, S., Thal, D. R., Goate, A., Strooper, B. D., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00487-8 · Cited by 75
Medial Temporal Lobe Subregional Atrophy in Aging and Alzheimer's Disease: A Longitudinal Study
Chauveau, L., Kuhn, E., Palix, C., Felisatti, F., Ourry, V., Sayette, V. D. L., Chételat, G., & de Florès, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.750154 · Cited by 81
Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Kalaitzakis, M. E., Walls, A. J., Pearce, R. K. B., & Gentleman, S. M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.005 · Cited by 72
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors
Bretteville, A., Marcouiller, F., Julien, C., Khoury, N. B. E., Petry, F. R., Poitras, I., Mouginot, D., Lévesque, G., Hébert, S. S., & Planel, E. (2012) · Scientific Reports · doi:10.1038/srep00480 · Cited by 70
Ryan, N. S., Biessels, G. J., Kim, L. G., Nicholas, J. M., Barber, P. A., Walsh, P., Gami‐Patel, P., Morris, H. R., de Bastos-Leite, A. J., Schott, J. M., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.026 · Cited by 72
Javanshiri, K., Waldö, M. L., Friberg, N., Sjövall, F., Wickerström, K., Haglund, M., & Englund, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180644 · Cited by 68
Fonteh, A. N., Ormseth, C. H., Chiang, J., Cipolla, M., Arakaki, X., & Harrington, M. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125597 · Cited by 72
Neurodegenerative diseases as proteinopathies-driven immune disorders
Lanuti, P., Ciccocioppo, F., Bologna, G., Ercolino, E., Pierdomenico, L., Simeone, P., Pieragostino, D., Boccio, P. D., Marchisio, M., & Miscia, S. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.268971 · Cited by 76
Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy
Buciuc, M., Botha, H., Murray, M. E., Schwarz, C. G., Senjem, M. L., Jones, D. T., Knopman, D. S., Boeve, B. F., Petersen, R. C., Jack, C. R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009722 · Cited by 71
Feleke, R., Reynolds, R. H., Smith, A. M., Tilley, B. S., Taliun, S. A. G., Hardy, J., Matthews, P. M., Gentleman, S., Owen, D. R., Johnson, M. R., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02343-x · Cited by 69
Amidst an amygdala renaissance in Alzheimer’s disease
Stouffer, K. M., Grande, X., Düzel, E., Johansson, M., Creese, B., Witter, M. P., Miller, M. I., Wisse, L. E. M., & Berron, D. (2023) · Brain · doi:10.1093/brain/awad411 · Cited by 72
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Benedet, A. L., Vrillon, A., Dumurgier, J., Cognat, E., Brum, W. S., Rahmouni, N., Stevenson, J., Servaes, S., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02659-w · Cited by 74
Cherbuin, N., Sachdev, P. S., & Anstey, K. J. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cdecf1 · Cited by 69
Nagao, S., Yokota, O., Ikeda, C., Takeda, N., Ishizu, H., Kuroda, S., Sudo, K., Terada, S., Murayama, S., & Uchitomi, Y. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0472-6 · Cited by 73
Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 72
The relationship between subcortical tau pathology and Alzheimer's disease
Attems, J., Thal, D. R., & Jellinger, K. A. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120034 · Cited by 72
Linking pathways in the developing and aging brain with neurodegeneration
Kovács, G. G., Adle‐Biassette, H., Milenković, I., Cipriani, S., van Scheppingen, J., & Aronica, E. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.045 · Cited by 69
A 6.4 Mb Duplication of the α-Synuclein Locus Causing Frontotemporal Dementia and Parkinsonism
Kara, E., Kiely, A. P., Proukakis, C., Giffin, N., Love, S., Hehir, J., Rantell, K. R., Pandraud, A., Hernandez, D. G., Nacheva, E. P., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.994 · Cited by 72
Landrieu, I., Smet‐Nocca, C., Amniai, L., Louis, J. V., Wieruszeski, J., Goris, J., Janssens, V., & Lippens, G. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021521 · Cited by 71
Turner, R. C., Lucke-Wold, B. P., Robson, M. J., Lee, J. M., & Bailes, J. E. (2016) · Brain Injury · doi:10.1080/02699052.2016.1193631 · Cited by 73
Immunotherapy in Parkinson’s disease: Current status and future directions
Chatterjee, D., & Kordower, J. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104587 · Cited by 74
Satoh, J., Tabunoki, H., & Arima, K. (2009) · Disease Markers · doi:10.1155/2009/618619 · Cited by 69
Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups
Kaivola, K., Shah, Z., Chia, R., International LBD Genomics Consortium, Black, S. E., Gan-Or, Z., Keith, J., Masellis, M., Rogaeva, E., Brice, A., et al. (2022) · Brain · doi:10.1093/brain/awab402 · Cited by 65
The three-dimensional landscape of cortical chromatin accessibility in Alzheimer’s disease
Bendl, J., Hauberg, M. E., Girdhar, K., Im, E., Vicari, J. M., Rahman, S., Fernando, M. B., Townsley, K. G., Dong, P., Misir, R., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01166-7 · Cited by 65
Translational approaches to understanding resilience to Alzheimer’s disease
Neuner, S. M., Telpoukhovskaia, M., Menon, V., O’Connell, K. M. S., Hohman, T. J., & Kaczorowski, C. C. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.02.005 · Cited by 68
“Historically, this has been done postmortem using classifications from autopsy-based neuropathological scores on standardized scales such as the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) score for neuritic plaques [78] and Braak staging of neurofibrillary tangles [79] in combination with antem…”
Methodde Ruyter, F. J. H., Morrema, T. H. J., den Haan, J., Bank, N. B., Twisk, J. W. R., de Boer, J. F., Scheltens, P., Boon, B. D. C., Thal, D. R., Rozemüller, A. J. M., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02525-1 · Cited by 70
Riederer, P. F., Nagatsu, T., Youdim, M. B. H., Wulf, M., Dijkstra, J. M., & Sian‐Hülsmann, J. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02630-9 · Cited by 71
Islam, T., Hill, E., Abrahamson, E. E., Servaes, S., Smirnov, D. S., Zeng, X., Sehrawat, A., Chen, Y., Kac, P. R., Kvartsberg, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03400-0 · Cited by 76
Is Tau Aggregation Toxic or Protective?
Congdon, E. E., & Duff, K. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-14415 · Cited by 70
Tau Aggregation in Alzheimer's Disease: What Role for Phosphorylation?
Lippens, G., Sillen, A., Landrieu, I., Amniai, L., Sibille, N., Barbier, P., Leroy, A., Hanoulle, X., & Wieruszeski, J.-M. (2007) · Prion · doi:10.4161/pri.1.1.4055 · Cited by 68
Tavares, I. A., Touma, D., Lynham, S., Troakes, C., Schober, M. S., Čaušević, M., Garg, R., Noble, W. J., Killick, R., Bódi, I., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448183 · Cited by 69
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease
Lithner, C. U., Lacor, P. N., Zhao, W.-Q., Mustafiz, T., Klein, W. L., Sweatt, J. D., & Hernandez, C. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.028 · Cited by 67
Verfaillie, S. C. J., Tijms, B. M., Versteeg, A., Benedictus, M. R., Bouwman, F. H., Scheltens, P., Barkhof, F., Vrenken, H., & van der Flier, W. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.10.007 · Cited by 70
Cisbani, G., Maxan, A., Kordower, J. H., Planel, E., Freeman, T. B., & Cicchetti, F. (2017) · Brain · doi:10.1093/brain/awx255 · Cited by 67
Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease
Phillips, J. S., Das, S. R., McMillan, C. T., Irwin, D. J., Roll, E. E., Da Re, F., Nasrallah, I. M., Wolk, D. A., & Grossman, M. (2018) · Human Brain Mapping · doi:10.1002/hbm.23874 · Cited by 68
Satoh, A., & Iijima, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.12.027 · Cited by 72
ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease
Lyssenko, N. N., & Praticò, D. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12220 · Cited by 67
Hoffman, G. E., Lee, D., Bendl, J. M., Prashant, N. M., Hong, A., Casey, C., Alvia, M., Shao, Z., Argyriou, S., Therrien, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75680-8 · Cited by 75
Zelaya, M. V., Pérez‐Valderrama, E., de Morentin, X. M., Tuñón, T., Ferrer, I., Luquín, M. R., Fernández‐Irigoyen, J., & Santamaría, E. (2015) · Oncotarget · doi:10.18632/oncotarget.6254 · Cited by 68
Sun, J., Xu, J., Cairns, N. J., Perlmutter, J. S., & Mach, R. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049483 · Cited by 67
Thal, D. R., von Arnim, C. A. F., Griffin, W. S. T., Mrak, R. E., Walker, L., Attems, J., & Arzberger, T. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1360-6 · Cited by 67
Self-citationEarly neuropsychological discriminants for Lewy body disease: an autopsy series
Yoshizawa, H., Vonsattel, J. P., & Honig, L. S. (2013) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304381 · Cited by 67
Michael, R., Lenferink, A. T. M., Vrensen, G. F. J. M., Gelpí, E., Barraquer, R. I., & Otto, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16002-3 · Cited by 68
The need to unify neuropathological assessments of vascular alterations in the ageing brain
Alafuzoff, I., Gelpi, E., Al-Sarraj, S., Arzberger, T., Attems, J., Bodi, I., Bogdanovic, N., Budka, H., Bugiani, O., Englund, E., et al. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.06.001 · Cited by 65
Self-citationCharacteristics of Dyshoric Capillary Cerebral Amyloid Angiopathy
Richard, E., Carrano, A., Hoozemans, J. J., van Horssen, J., van Haastert, E. S., Eurelings, L. S., de Vries, H. E., Thal, D. R., Eikelenboom, P., van Gool, W. A., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181fab558 · Cited by 71
mTOR Hyperactivation in Down Syndrome Hippocampus Appears Early During Development
Iyer, A. M., van Scheppingen, J., Milenkovic, I., Anink, J. J., Adle-Biassette, H., Kovacs, G. G., & Aronica, E. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000083 · Cited by 69
Neuropathology and cognitive performance in self-reported cognitively healthy centenarians
Ganz, A. B., Beker, N., Hulsman, M., Sikkes, S. A. M., NBB, Scheltens, P., Smit, A. B., Rozemüller, A. J. M., Hoozemans, J. J. M., & Holstege, H. H. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0558-5 · Cited by 69
PET imaging of mGluR5 in Alzheimer’s disease
Mecca, A. P., McDonald, J. W., Michalak, H. R., Godek, T. A., Harris, J. E., Pugh, E., Kemp, E. C., Chen, M.-K., Salardini, A., Nabulsi, N., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-0582-0 · Cited by 66
Cornblath, E. J., Li, H. L., Changolkar, L., Zhang, B., Brown, H. J., Gathagan, R. J., Olufemi, M. F., Trojanowski, J. Q., Bassett, D. S., Lee, V. M. Y., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg6677 · Cited by 66
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
TDP-43 pathology is associated with increased tau burdens and seeding
Tomé, S. O., Tsaka, G., Ronisz, A., Ospitalieri, S., Gawor, K., Gomes, L. A., Otto, M., Arnim, C. A. F. V., Damme, P. V., Bosch, L. V. D., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00653-0 · Cited by 74
Mandler, M., Walker, L., Santic, R., Hanson, P. S., Upadhaya, A. R., Colloby, S. J., Morris, C. M., Thal, D. R., Thomas, A. J., Schneeberger, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1296-9 · Cited by 65
The inferior olivary nucleus: A postmortem study of essential tremor cases versus controls
Louis, E. D., Babij, R., Cortes, E. P., Vonsattel, J., & Faust, P. L. (2013) · Movement Disorders · doi:10.1002/mds.25400 · Cited by 66
Gratuze, M., Julien, J., Petry, F. R., Morin, F., & Planel, E. (2017) · Scientific Reports · doi:10.1038/srep46359 · Cited by 68
Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration
Seo, S. W., Thibodeau, M., Perry, D. C., Hua, A. Y., Sidhu, M., Sible, I. J., Vargas, J. N. S., Gaus, S. E., Rabinovici, G. D., Rankin, K. D., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005163 · Cited by 67
Carbonell, F., Iturria‐Medina, Y., & Evans, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00037 · Cited by 65
Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington’s disease
Gratuze, M., Noël, A., Julien, C., Cisbani, G., Milot-Rousseau, P., Morin, F., Dickler, M., Goupil, C., Bezeau, F., Poitras, I., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu456 · Cited by 65
Tredici, K. D., & Braak, H. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.008 · Cited by 68
Self-citationBeker, N., Ganz, A. B., Hulsman, M., Klausch, T. L. T., Schmand, B. A., Scheltens, P., Sikkes, S. A. M., & Holstege, H. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.31654 · Cited by 65
Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies
Koss, D. J., Erskine, D., Porter, A., Palmoski, P., Menon, H., Todd, O., Leite, M., Attems, J., & Outeiro, T. F. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01403-x · Cited by 65
Mossige, I., Valnes, L. M., Storås, T. H., Emblem, K. E., Eide, P. K., & Ringstad, G. A. (2026) · Radiology · doi:10.1148/radiol.252070 · Cited by 65
Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Fish, K. N., Ikonomović, M. D., Hamilton, R. L., Kofler, J., Klunk, W. E., López, O. L., & Sweet, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131166 · Cited by 67
Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease
Vermeiren, Y., Dam, D. V., Aerts, T., Engelborghs, S., & Deyn, P. P. D. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140309 · Cited by 68
Cai, S., Chong, T., Zhang, Y., Li, J., von Deneen, K. M., Ren, J., Dong, M., & Huang, L. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2015.00471 · Cited by 68
Zeineddine, R., & Yerbury, J. J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00277 · Cited by 67
Hyposmia in G2019S LRRK2-related parkinsonism
Silveira‐Moriyama, L., Guedes, L. C., Kingsbury, A. E., Ayling, H., Shaw, K., Barbosa, E. R., Bonifati, V., Quinn, N. P., Abou‐Sleiman, P. M., Wood, N. W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326575.20829.45 · Cited by 65
Added diagnostic value of CSF biomarkers in differential dementia diagnosis
Bastard, N. L., Martin, J., Vanmechelen, E., Vanderstichele, H., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.017 · Cited by 67
Deleglise, B., Magnifico, S., Duplus, E., Vaur, P., Soubeyre, V., Belle, M., Vignes, M., Viovy, J., Jacotot, E. D., Peyrin, J., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0145-3 · Cited by 70
Advances in MRI Biomarkers for the Diagnosis of Alzheimer’s Disease
Kehoe, E. G., McNulty, J. P., Mullins, P. G., & Bokde, A. L. W. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.14.42 · Cited by 70
Molecular estimation of neurodegeneration pseudotime in older brains
Mukherjee, S., Heath, L. M., Preuß, C., Jayadev, S., Garden, G. A., Greenwood, A. K., Sieberts, S. K., Jager, P. L. D., Ertekin‐Taner, N., Carter, G. W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19622-y · Cited by 62
Desmarais, P., Gao, A. F., Lanctôt, K. L., Rogaeva, E. A., Ramirez, J., Herrmann, N., Stuss, D. T., Black, S. E., Keith, J. L., & Masellis, M. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00869-6 · Cited by 63
Haque, R., Watson, C. M., Liu, J., Carter, E. K., Duong, D. M., Lah, J. J., Wingo, A. P., Roberts, B. R., Johnson, E. C. B., Saykin, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg4122 · Cited by 64
Schmitt, A., Leonardi‐Essmann, F., Durrenberger, P. F., Parlapani, E., Schneider-Axmann, T., Spanagel, R., Arzberger, T., Kretzschmar, H. A., Herrera‐Marschitz, M., Gruber, O., et al. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.530690 · Cited by 64
Self-citationInteraction between -Synuclein and Other Proteins in Neurodegenerative Disorders
Jellinger, K. A. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/371893 · Cited by 64
Widespread distribution of tauopathy in preclinical Alzheimer's disease
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 65
Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury
Mohamed, A. Z., Cumming, P. D., Götz, J., & Nasrallah, F. A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4241-7 · Cited by 68
Liu, M., Paranjpe, M. D., Zhou, X., Duy, P. Q., Goyal, M. S., Benzinger, T. L. S., Lu, J., Wang, R., & Zhou, Y. (2019) · Theranostics · doi:10.7150/thno.35366 · Cited by 67
Extracellular tau induces microglial phagocytosis of living neurons in cell cultures
Pampuščenko, K., Morkūnienė, R., Šneideris, T., Smirnovas, V., Budvytytė, R., Valinčius, G., Brown, G. C., & Borutaitė, V. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14940 · Cited by 64
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments
Kaniyappan, S., Tepper, K., Biernat, J., Chandupatla, R., Hübschmann, S., Irsen, S. H., Bicher, S., Klatt, C., Mandelkow, E., & Mandelkow�, E. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00389-1 · Cited by 65
Altered Functional Connectivity of Insular Subregions in Alzheimer’s Disease
Liu, X., Chen, X., Zheng, W., Xia, M., Han, Y., Song, H., Li, K., Yong He, A., & Wang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00107 · Cited by 61
Metadata
- Authors
- Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K.
- Affiliations
- Goethe University Frankfurt (DE)
- Kuopio University Hospital (FI)
- Institut für Neuropathologie (DE)
- Corresponding author
- Braak, Heiko
- Venue
- Acta Neuropathologica
- Published
- 2006-08-12
- Volume
- 112
- Issue
- 4
- Pages
- 389-404
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3906709
- OpenAlex
- W2093650784
- Cited by
- 3,172
- References
- 101
- Citations by year
- 2026: 218 · 2025: 259 · 2024: 334 · 2023: 254 · 2022: 251 · 2021: 261 · 2020: 228 · 2019: 205 · 2018: 157 · 2017: 135 · 2016: 140 · 2015: 118 · 2014: 134 · 2013: 95 · 2012: 77
- FWCI
- 34.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Acta Neuropathologica (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission (LSHM-CT-2004-503039)
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neurofibrillary pathology, disease staging, AT8 antibody, immunocytochemistry, paraffin sections, silver staining
- MeSH terms
- Alzheimer Disease, Humans, Immunohistochemistry, Amyloid beta-Peptides, Paraffin Embedding, Tissue Fixation, Neurofibrillary Tangles, tau Proteins, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
